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Abstract: A key process in the regulation of protein activities and thus cellular signaling 
pathways is the modification of proteins by post-translational mechanisms. Knowledge 
about the enzymes (writers and erasers) that attach and remove post-translational 
modifications, the targets that are modified and the functional consequences elicited by 
specific modifications, is crucial for understanding cell biological processes. Moreover 
detailed knowledge about these mechanisms and pathways helps to elucidate the molecular 
causes of various diseases and in defining potential targets for therapeutic approaches. 
Intracellular adenosine diphosphate (ADP)-ribosylation refers to the nicotinamide adenine 
dinucleotide (NAD+)-dependent modification of proteins with ADP-ribose and is catalyzed 
by enzymes of the ARTD (ADP-ribosyltransferase diphtheria toxin like, also known as 
PARP) family as well as some members of the Sirtuin family. Poly-ADP-ribosylation is 
relatively well understood with inhibitors being used as anti-cancer agents. However, the 
majority of ARTD enzymes and the ADP-ribosylating Sirtuins are restricted to catalyzing 
mono-ADP-ribosylation. Although writers, readers and erasers of intracellular mono-ADP-
ribosylation have been identified only recently, it is becoming more and more evident that this 
reversible post-translational modification is capable of modulating key intracellular processes 
and signaling pathways. These include signal transduction mechanisms, stress pathways 
associated with the endoplasmic reticulum and stress granules, and chromatin-associated 
processes such as transcription and DNA repair. We hypothesize that mono-ADP-ribosylation 
controls, through these different pathways, the development of cancer and infectious diseases. 
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1. Introduction  
Adenosine diphosphate (ADP)-ribosylation is a reversible post-translational modification (PTM) of 
proteins that is catalyzed by ADP-ribosyltransferases (ARTs) and certain members of the Sirtuin 
family [1–3]. In ADP-ribosylation reactions, the cofactor nicotinamide adenine dinucleotide (NAD+) is 
used to covalently attach residues of ADP-ribose to specific acceptor amino acids of substrate proteins 
with release of nicotinamide. ARTs share a structurally conserved catalytic domain. Based on the 
homology of these catalytic domains either to cholera or to diphtheria toxin, mammalian  
ARTs are categorized as members of the ADP-ribosyltransferase cholera toxin-like (ARTCs) or 
diphtheria toxin-like (ARTDs) sub-families, respectively. ARTC enzymes are GPI-anchored 
extracellular or secreted enzymes that transfer single ADP-ribose residues to their substrates [4,5]. In 
contrast, ARTDs are intracellular enzymes able to transfer either a single ADP-ribose residue to an 
acceptor amino acid, a process referred to as mono-ADP-ribosylation (MARylation), or they are able 
to attach additional ADP-ribose residues with ADP-ribose being the acceptor, resulting in either linear 
or branched chains of ADP-ribose (poly-ADP-ribosylation or PARylation) [6]. The founding member 
of the ARTD family, ARTD1, was first shown to PARylate itself and substrate proteins, which led to 
the initial designation PARP1 for poly-ADP-ribose polymerase 1. The family of proteins with related 
catalytic domains was therefore termed PARP family. However, after the discovery of sub-family 
members being capable of only MARylation, a new nomenclature and classification has been proposed 
that we shall use here [7] (Table 1). The ability of intracellular ART enzymes to form ADP-ribose 
polymers depends on the defined H-Y-E amino acid signature in the catalytic center. Enzymes with 
this signature transfer multiple ADP-ribose units in an iterative process to their substrates using the 
glutamate to activate NAD+. The catalytic glutamate residue is replaced in enzymes of the mono-
ARTD group (H-Y-E variants). These enzymes instead employ a glutamate residue of the substrate for 
the transfer of ADP-ribose (substrate-assisted catalysis), which when modified is then no longer 
available for the activation of additional NAD+ cofactor molecules [6]. Therefore, besides ARTD1, 
ARTD2 (PARP2), ARTD5 (PARP5A, Tankyrase 1) and ARTD6 (Tankyrase 2) synthesize poly- or 
oligo-ADP-ribose chains, whereas ARTD7/8 (PARP15, PARP14), ARTD10–12 (PARP10–12), and 
ARTD14–17 (PARP8, -7, -16, -6) are classified as mono-ADP-ribosyltransferases (mono-ARTDs) [6,7]. 
Additional amino acid substitutions as in ARTD9 and ARTD13 (PARP9, -13) prohibit NAD+-binding 
and render these proteins catalytically inactive [6,8]. Although ARTD3 and ARTD4 (PARP3, -4) were 
initially proposed to have PARylation activity based on their classical H-Y-E signature [6], 
MARylation activity for both enzymes has been reported [9,10], suggesting that other alterations in the 
active center are responsible for the lack of PARylation activity or that substrate specific effects 
restrict these enzymes to MARylation (Table 1).  
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Table 1. MARylation in signaling and disease 
Protein 
Enzymatic 
activity 
Cellular process/ pathway Disease-related function 
ARTD3 MAR DNA repair [11] Not reported 
ARTD4  
(PARP4, vPARP) 
MAR Vault particles [12] 
Multidrug resistance? [13–16] 
Innate immunity? [13] 
ARTD7  
(PARP15, BAL3) 
MAR Component of stress granules [17] Not reported 
ARTD8  
(PARP14, BAL2, 
CoaSt6) 
MAR 
IL-4/STAT6 signaling [18–20] 
JNK signaling [21] 
TH cell differentiation [22–24] 
Component of stress granules [17] 
Promotes cell survival in B cells/multiple myeloma and 
lymphomagenesis [21,25,26] 
Allergic airway disease [22] 
ARTD9  
(PARP9) 
inactive IFNγ/STAT1 signaling [27–29] Risk factor in DLBCL [27,28] 
Cell survival and chemoresistance [27–29] 
ARTD10 
(PARP10) 
MAR 
NF-κB signaling [30] 
Translation [31] 
Autophagy? [32] 
GSK3β signaling? [33] 
Regulation of apoptosis [34] 
Inflammation? [30] 
IFN-stimulated gene, inhibition of viral replication [31] 
ARTD12 
(PARP12) 
MAR 
Translation [31] 
NF-κB signaling? [35] 
Autophagy? [35] 
Component of stress granules 
[17] 
IFN-stimulated gene, inhibition of viral replication [31] 
 
ARTD13 
(PARP13, ZAP, 
ZC3HAV1) 
inactive 
mRNA regulation and 
miRNA silencing [36] 
Component of stress granules 
[17] 
Viral defense [36] 
 
ARTD14 
(PARP7, TiPARP) 
MAR 
AHR signaling [37–40] 
Translation [31] 
 
TCCD-induced hepatotoxicity [40] 
Inhibition of viral replication [31,41] 
ARTD15 
(PARP16) 
MAR Unfolded protein response [42] Not reported 
ARTD16 
(PARP8) 
MAR Unclear Not reported 
ARTD17 
(PARP6) 
MAR 
Regulates cell cycle progression 
[43] 
Inhibits cell proliferation, survival benefit in colorectal 
cancer [43] 
SIRT4 MAR Glutamine metabolism [44,45] Tumor-suppressive [45,46] 
SIRT6 MAR 
DNA repair [47–49] 
Retrotransposon silencing [50] 
Tumor suppressive [50–57] 
and oncogenic functions [58,59] 
MACROD1 
(LRP16) 
Hydrolase 
ERα signaling [60,61]  
AR signaling [62] 
Promotes cell proliferation [60,62] 
Metastasis, invasion and survival in gastric and 
colorectal cancer [63,64]. 
MACROD2 
(C20ORF133) 
Hydrolase Unclear Tamoxifen-resistance in breast cancer cell lines [65] 
TARG1 
(C6ORF130, OARD1) 
Hydrolase DNA repair? [66] Neurodegeneration [66] 
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Besides ARTDs intracellular MARylation has also been ascribed to certain members of the Sirtuin 
family, namely SIRT4 and SIRT6 [44,67]. The mammalian Sirtuin family encompasses seven 
members, which have been originally identified to catalyze lysine deacetylation by the use of NAD+ as 
a co-factor thereby producing O-acetyl-ADP-ribose and nicotinamide [68,69]. A first indication that 
Sirtuins can function as mono-ARTs stems from the analysis of Saccharomyces cerevisiae Sir2, human 
SIRT2, and bacterial Sirtuins, which were shown to transfer ADP-ribose from NAD+ to substrates in 
biochemical assays [70,71]. More recently, SIRT4 and SIRT6 were described as mono-ARTs, thereby 
catalyzing MARylation [44,67].  
So far, the evidence that MARylation catalyzed by mono-ARTDs and Sirtuins occurs in cells is 
limited due to the general difficulties to detect MARylation. While in vitro the use of radioactively 
labeled or chemically modified NAD+ can be used, the analysis in cells is more complex. Several 
antibodies are generally used to detect PAR chains synthesized in cells, but presently no comparable 
tools are available for MARylation. Moreover so far no consensus sequences could be defined, unlike e.g. 
with phosphorylation consensus sites identified for kinases, which has greatly facilitated their analysis. 
Thus the analysis of intracellular MARylation, i.e. the identification of substrates and modified sites, 
relies mainly on mass spectrometry (MS) approaches and on selective reader domains. The last years 
have shown considerable progress in the development of MS protocols that address the complexity of 
attachment sites with multiple amino acids described as potential sites of modification. Of note is also 
that ADP-ribose itself is challenging due to its behavior in different MS protocols and the potential to 
produce a number of different fragments making the analysis tedious. Moreover, the lack of efficient 
methods to analyze MARylation also poses a burden on the verification of MARylated substrates 
identified in various screens. It is important for the reader to realize these obstacles when discussing 
the functionality of intracellular MARylation. We refer to excellent recent reviews that discuss the 
detection and analysis of MARylation in detail [72–74].  
The structural analysis of the enzymes of the ARTD sub-family revealed a multitude of other 
functional domains, likely reflecting the involvement of these enzymes in a variety of cellular 
processes [7,75]. In contrast the Sirtuins appear to be less complex. Besides the catalytic domain, both 
the N- and the C-terminal regions of SIRT4 and SIRT6 lack recognizable domains, suggesting that 
these enzymes use targeting subunits for selective activities [76]. Functions of polymer forming 
ARTDs and PARylation, with a variety of protein domains recognizing this PTM and enzymes capable 
of PAR degradation, are relatively well understood and range from the regulation of signaling and 
metabolism to the control of chromatin-related processes including transcription and DNA repair [3,77]. 
In contrast, the existence of ARTD enzymes being restricted to MARylation has only become apparent 
in the last decade, with ARTD10 being the founding member of this group [6]. Similarly, the 
identification of MARylation by Sirtuins is rather recent, as described above. In comparison to 
PARylation, relatively little is known about functions of MARylation so far and the lack of suitable 
tools for the detection of mono-ADP-ribosylated proteins, as detailed above, is impeding the analysis 
of intracellular MARylation and the identification of substrates. However, an increasing number of 
studies provides evidence that also MARylation serves as reversible PTM that can be read by specific 
protein domains (readers) and removed by MAR-specific hydrolases (erasers). Up-to-date, roles in the 
regulation of cell proliferation, apoptosis, signaling, metabolism, transcription and DNA repair have 
been described [1]. The so far identified reader and eraser proteins for intracellular MARylation share 
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a common structural fold, the macrodomain. Indeed a role for macrodomains in ADP-ribose biology is 
becoming very well established. Some bind to free ADP-ribose or -derivatives, others exert catalytic 
activity towards ADP-ribosylated proteins or ADP-ribose derivatives. In addition some macrodomains 
show specificity for either MAR or PAR [78]. The macrodomains 2 and 3 of ARTD8, which are 
devoid of catalytic activity, have been identified recently as binding modules specific for at least some 
MARylated substrates [79]. So far, at least three enzymes are known to exist that are able to hydrolyze 
the bond between ADP-ribose and acidic acceptor amino acids, namely the two related MACROD1 
and MACROD2, as well as C6ORF130/TARG1 [66,80,81]. Whether these hydrolases are active 
against all different MARylations, including those catalyzed by Sirtuins, has not been resolved. In the 
following we focus on the ARTD and Sirtuin family members with mono-ART activity and on the 
enzymes that can remove mono-ADP-ribose from substrate proteins. We review the roles of 
intracellular MARylation for the regulation of signaling pathways and discuss the relevance of this 
reversible PTM for disease.  
2. Regulation of Signaling Pathways and Gene Expression by MARylation  
2.1. ARTD8 Regulates IL4/STAT6 Signaling 
ARTD8 (PARP14/BAL2/CoaSt6) was initially described as a member of the family of  
B-aggressive-lymphoma (BAL) proteins [82]. Then it was identified in a yeast two-hybrid screen as an 
interaction partner of Signal Transducer and Activator of Transcription (STAT) 6, co-activating IL-4-
induced STAT6-dependent transcription. In this report, it was therefore termed CoaSt6 (collaborator of 
STAT6) (Figure 1) [18]. The IL-4/STAT6 signaling pathway is an important immune regulatory 
pathway affecting multiple cell types. STAT6-induced transcriptional programs mediate for example 
TH2 differentiation and allergic inflammatory TH2 effector responses in T cells as well as antibody 
class switching to the IgE isotype in B cells [83]. Upon binding of the cytokines IL-4 and IL-13 to 
receptors containing the IL-4Rα-subunit, STAT6 is subjected to JAK-mediated phosphorylation, 
resulting in homodimerization of phosphorylated STAT6 and its translocation into the nucleus, where 
it activates the transcription of target genes [83]. ARTD8 modulates this pathway depending on its 
macro- and C-terminal catalytic domains [18]. Later it was shown that ADP-ribosylation activity 
seems to be important for its co-activator function. A catalytically inactive mutant does not activate 
transcription from a STAT6 reporter plasmid and inhibition of ARTD activity by 3-aminobenzamide, 
an unspecific ARTD inhibitor, blocks IL-4 induced transcription [19]. According to the current model, 
ARTD8 acts as a “transcriptional switch” for STAT6-dependent transcription. In the unstimulated 
state, ARTD8 is associated with promoters of STAT6 responsive genes, interacting with the histone 
deacetylases HDAC2 and HDAC3, thereby repressing transcription. How precisely ARTD8 is 
recruited to such promoters has not been fully resolved. Stimulation of cells with IL-4 activates 
ARTD8 catalytic activity by an unknown mechanism, resulting in MARylation of HDAC2 and 
HDAC3. ARTD8 and HDACs are thereupon released from the promoter, allowing the STAT6 dimer 
to bind and activate transcription [20]. Thus these findings suggest that ARTD8 is a subunit of a 
transcriptional switch that controls HDAC activity and thus potentially histone acetylation in a promoter 
specific manner. Further studies will have to address the precise mechanism that is controlled by ARTD8 
and in which cellular processes this switch is operational. 
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2.2. ARTD10 Modulates GSK3β Kinase Activity and NF-κB Signaling 
ARTD10 has been identified in a screen for interaction partners of the oncoprotein c-MYC [84] and 
is the founding member of the group of mono-ARTDs [6]. Recent work revealed that ARTD10 plays 
important roles in the regulation of several cellular processes, including the control of cell 
proliferation, NF-κB signaling and DNA repair [85]. ARTD10 possesses a functional C-terminal 
catalytic domain, an N-terminally located RNA-recognition motif (RRM), glycine-rich and  
glutamate-rich regions, a nuclear export sequence (NES) and a region mediating nuclear uptake 
responsible for nuclear-cytoplasmic shuttling, and two ubiquitin-interaction motifs (UIMs) [84]. A 
protein array-based screen for ARTD10 substrates revealed that ARTD10 might target a variety of 
kinases as well as receptors and growth factors [33], which could account for the above-described 
biological effects. Several of these kinases have been validated in independent experiments, one of 
which is GSK3β, a serine/threonine-kinase regulating many cellular processes [86,87]. MARylation of 
GSK3β by ARTD10 in vitro and overexpression of ARTD10 in cells reduces GSK3βs kinase activity. 
Conversely, increased kinase activity can be observed after ARTD10 knockdown and after overexpression 
of the MAR-specific hydrolase MACROD2, which was shown to remove MARylation from GSK3β  
in vitro [33,81]. Altogether, this provides first evidence that MARylation does indeed take place in cells 
and is able to regulate enzymatic activity. Whether ARTD10-dependent MARylation affects  
GSK3β-related signaling pathways, as for example WNT signaling, still needs to be investigated in 
future studies. Furthermore, the enrichment of ARTD10 (and ARTD8) substrates for kinases in the in vitro 
screen suggests that crosstalk exists between MARylation and other PTMs, including phosphorylation. 
ARTD10 itself is phosphorylated by multiple kinases, suggesting that it is controlled by several 
signaling pathways (our unpublished findings).  
With its two ubiquitin-interaction motifs, a unique feature of ARTD10 among the ARTDs, 
ARTD10 interacts with K63-linked poly-ubiquitin chains [30]. K63-linked poly-ubiquitin plays 
important roles for example in the NF-κB signaling pathway [88]. NF-κB proteins are dimeric 
transcription factors that regulate the expression of genes in response to stimulation of cells with  
pro-inflammatory cytokines including IL-1β and TNFα as well as pathogen-associated molecular 
patterns (PAMPs) such as lipopolysaccharide (LPS). In the unstimulated state, IκB sequesters NF-κB 
proteins in the cytosol. Upon activation of the signaling pathway, the IKK complex consisting  
of NEMO, IKKα and IKKβ is activated and phosphorylates IκB. IκB is then targeted for  
proteasome-mediated degradation, allowing for the release of the NF-κB p65/p50 dimer to translocate 
into the nucleus and activate the transcription of target genes [89]. ARTD10 has been shown to 
interfere with NF-κB signaling (Figure 1). In HeLa cells, the activation of the NF-κB target genes 
encoding for IκBα and IL-8 after stimulation with IL-1β is reduced upon overexpression of ARTD10, 
whereas ARTD10-GW/ΔUIM, a mutant that is catalytically inactive and fails to interact with  
K63-linked poly-ubiquitin, has no effect. Consistently, ARTD10 knockdown in U2OS cells enhances 
the expression of these two NF-κB target genes. This is in agreement with ARTD10 acting as  
a repressor of NF-κB signaling dependent on its catalytic activity and on its ability to interact with  
K63-linked poly-ubiquitin. Intervention by ARTD10 is thought to take place at the level of NEMO 
poly-ubiquitination. K63-poly-ubiquitination of NEMO is essential for signal propagation and  
IKK-complex activation [90]. ARTD10 is probably recruited to K63-linked poly-ubiquitin chains via 
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its two UIMs, promoting close contact with and subsequently MARylation of NEMO, thereby 
preventing its poly-ubiquitination and further downstream signaling [30].  
 
Figure 1. Functions of mono-ADP-ribosylating ARTD (ADP-ribosyltransferase diphtheria 
toxin-like) enzymes and of mono-ADP-ribosylating Sirtuins in signaling. Nuclear 
functions have been reported for ARTD8, ARTD9, ARTD10, ARTD14 and for SIRT6. 
ARTD8 has been described to regulate Signal Transducer and Activator of Transcription 
(STAT) 6-dependent gene expression, whereas ARTD8 and ARTD9 influence STAT1-
dependent gene expression. Besides regulating STAT transcription factors, ARTD8 as well 
as ARTD10 and SIRT6 have been linked to DNA damage repair. ARTD14 interferes with 
AHR/ARNT (aryl hydrocarbon receptor/AHR nuclear translocator) driven gene 
expression. Moreover, SIRT6 regulates retrotransposon silencing. ARTD15 is localized to 
either the nuclear envelope where it influences nuclear-cytoplasmic shuttling or to the 
endoplasmic reticulum (ER) where it controls the unfolded protein response by 
modification of IRE1α (inositol requiring enzyme 1) and PERK (protein kinase RNA-like ER 
kinase). ARTD7, ARTD8 and ARTD12 are associated with stress granule formation. In 
addition, ARTD12 localizes to the autophagy receptor p62 and might be a player in the 
regulation of the NF-κB signaling pathway. Similarly, ARTD10 co-localizes with p62 in 
an ubiquitin-dependent manner and represses NF-κB signaling. ARTD10, ARTD12 and 
ARTD14 have been suggested to inhibit translation as well as viral replication. SIRT4 is 
localized to mitochondria and regulates glutamate dehydrogenase (GDH) activity and 
glutamine metabolism. For more details see the text.  
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2.3. ARTD14 Regulates AHR Signaling 
ARTD14 (PARP7, TiPARP) has been identified in a screen for TCCD  
(2,3,7,8-Tetrachlorodibenzo-p-dioxin)-inducible genes [37]. TCCD is an environmental pollutant 
arising from industrial processes that elicits toxic responses in animals and humans. TCCD causes 
these effects by binding to the cytoplasmic aryl hydrocarbon receptor (AHR). Once activated by ligand 
binding, AHR translocates into the nucleus where it dimerizes with its binding partner ARNT (AHR 
nuclear translocator) and acts as a transcription factor. Target genes include cytochrome P450 
encoding genes but also ARTD14 is induced upon TCCD treatment [37,38]. Further research has 
shown that ARTD14 is itself regulating AHR signaling in a negative feedback loop by acting as a 
transcriptional repressor (Figure 1) [39]. AHR can also serve as a substrate for ARTD14 [40]. 
However, whether ARTD14 regulates AHR activity or stability by MARylating waits to be 
investigated. It might promote proteasome-mediated degradation of AHR, be tethered to AHR 
response elements by interacting with AHR and thus interfere with a chromatin regulated process, or 
bind to the promoter directly mediated by its zinc-finger domain. The latter is suggested by the finding 
that its transcriptional co-repressor function depends on the zinc-finger domain and on the catalytic 
domain [39]. Interestingly, overexpressed MACROD1, but not MACROD2, is able to reverse the 
repressive effect of ARTD14 in a reporter gene assay and interacts with AHR [40]. Of note is that 
MACROD1 is mainly mitochondrial but the overexpressed protein is also detectable in the nucleus. 
Whether this is also true for the endogenous protein, e.g. in response to specific signals, has not been 
resolved. This suggests that MARylation by ARTD14 serves as an important PTM in the pathway 
controlling the response to environmental toxins such as dioxin and that MACROD1 might antagonize the 
repressive effect by removing MAR, either from ARTD14, AHR or other so far unidentified substrates.  
2.4. MARylation in the Unfolded Protein Response 
Upon accumulation of unfolded proteins in the endoplasmic reticulum (ER) lumen, a process that 
elicits ER stress, the unfolded protein response (UPR) is activated [91,92]. Key players of the UPR 
sensing the overload of unfolded polypeptides are the two kinases IRE1α (inositol requiring enzyme 1) 
and PERK (protein kinase RNA-like ER kinase) as well as the transcription factor ATF6 (activating 
transcription factor 6) [91,92]. Luminal portions of IRE1α and PERK are associated with the chaperone 
BiP (binding immunoglobulin protein, also GRP78) [93]. Along with binding to increasing amounts of 
unfolded proteins during ER stress, BiP dissociates from IRE1α and PERK. The activation of these 
kinases during the UPR results in several different cellular consequences, including inhibition of 
translation to reduce the amount of incoming unfolded proteins as well as increased expression of 
proteins that help to promote the folding capacity of the ER [91,92,94]. ARTD15 (PARP16) was 
characterized as a mono-ADP-ribosyltransferase with a C-terminal transmembrane domain being 
localized to the ER membrane and the nuclear envelope (Figure 1) [42,95]. Accordingly, functions for 
ARTD15 have been described in nuclear-cytoplasmic transport as well as in the UPR [42,95]. ARTD15 
knockdown results in increased sensitivity to ER stress. ARTD15 is associated with IRE1α and PERK 
and activated under ER stress conditions resulting in MARylation of IRE1α and PERK in their 
cytosolic portions. Modification of both kinases with mono-ADP-ribose is increasing their kinase 
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activity and enhancing downstream effects. Furthermore, in the ER lumen, the chaperone BiP remains 
bound to IRE1α and PERK when ARTD15 is depleted, arguing for a role of the luminal C-terminus of 
ARTD15 in BiP release [42]. An alternative model worth considering and testing is that the 
MARylation of these transmembranous kinases in the cytosolic portion induces a structural change in 
the luminal domain, which mediates interaction with BiP, resulting in reduced affinity. BiPs chaperone 
activity seems to be itself regulated by arginine-specific ADP-ribosylation. Modification of BiP at 
specific arginine residues was proposed to prevent interaction with unfolded proteins. The luminal BiP 
pool could thus be rapidly regulated by reversible ADP-ribosylation and serve as a buffer to quickly 
respond to changing levels of unfolded proteins in the ER [96]. Because ARTC enzymes passage 
through the ER en route to the outer leaflet of the plasma membrane and the extracellular space and 
because these enzymes modify arginines [4], it is possible that BiP proteins are modified by this 
sub-family of mono-ARTs. Indeed, a recent study demonstrates ARTC1 to be mainly localized to the 
ER. During ER stress induction with dithiothreitol or thapsigargin, which results in a reduced protein 
flux into the ER, ARTC1 is transiently up-regulated. This promotes ADP-ribosylation and therefore 
inactivation of BiP [97]. The postulated rapid removal of the MARylation of BiP when the protein load 
is increasing again suggests that also a mono-ADP-ribosylhydrolase is present in the ER that will be 
interesting to identify. Together these studies define the ER as a subcellular site that involves 
MARylation in protein quality control.  
2.5. MARylation in Response to Genotoxic Stress 
The role of PARylation in response to DNA damage is well studied. Mainly ARTD1 but also 
ARTD2 are sensing damaged DNA and reacting to the damage by auto-PARylation and PARylation of 
surrounding chromatin-associated proteins, in particular core histones [3]. PARylation leads to an 
opening of the chromatin and serves as a scaffold for the recruitment of repair factors, enabling 
efficient DNA repair. Knowledge about the function of ADP-ribosylation in DNA repair is so far 
mainly restricted to the polymer-forming ARTD family members. However, several recent reports 
provide insights into a role of MARylation in response to genotoxic stress. Knockdown of ARTD10 in 
HeLa cells results in enhanced sensitivity to DNA damage induced by mitomycin C, hydroxyurea 
(HU) or UV light treatment. Increased γ-H2AX, phospho-RPA and RAD51 foci formation has been 
observed under ARTD10 knockdown conditions [98]. These are markers to indicate DNA damage and 
because of the prolonged foci formation reduced DNA repair is assumed in conditions with reduced 
ARTD10 expression. As a component of the replication machinery, PCNA acts as a master regulator 
of replication and coordinates DNA repair and resumption of DNA replication at stalled replication 
forks [99]. ARTD10 was shown to interact with PCNA mediated by a region in ARTD10 termed  
PIP-box. The interaction with PCNA is further strengthened by interaction of ARTD10’s UIMs with 
ubiquitinated PCNA [98]. ARTD10 seems to be important for the restart of the DNA replication 
machinery after replication fork stalling. ARTD10 is important for maintaining PCNA ubiquitination 
levels by an as yet unknown mechanism, favoring the recruitment of error-prone translesion synthesis 
polymerases to stalled replication forks. Catalytic activity seems to be important for this process 
although relevant substrates have not been identified so far [98]. In addition to ARTD10, ARTD8 
interacts with PCNA in cells, preferentially when these are in the S-phase of the cell cycle [100]. 
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Similar to ARTD10, ARTD8 depletion enhances the sensitivity of cells to replication stress upon HU 
or UV treatment and accordingly more cells exhibit γ-H2AX foci formation in response to HU/UV 
treatment. ARTD8 is as well important for the restart of replication after replication fork stalling. In 
contrast to ARTD10, ARTD8 regulates DNA strand break repair via homologous recombination (HR). 
Interaction of one of the MAR-specific reader domains of ARTD8, macro2, with RAD51 was 
demonstrated. It is argued that RAD51 acts as an ARTD8 substrate during HR and thus the interaction 
with macro2 might be part of a feedback loop. How relevant these interactions are for proper HR 
repair remains to be investigated [100]. 
Besides ARTD8 and ARTD10, SIRT6 has also been linked to genotoxic stress [47]. Although most 
of its molecular functions, e.g. in the regulation of stress-responsive and metabolism-related genes or 
its roles in base excision repair and double strand break (DSB) repair, have been ascribed to its 
deacetylase activity so far [101–103], recent research has linked the MARylation activity of SIRT6 to 
DNA repair [47,48]. SIRT6 maintains genome integrity by regulating DNA repair underlined by the 
fact that cells lacking SIRT6 are hampered to repair DSBs and mice devoid of SIRT6 exhibit impaired 
base excision repair [49,104]. Under oxidative stress SIRT6 is recruited to sites of DNA damage where 
it stimulates non-homologous end joining as well as HR. SIRT6 mutants allowing the distinction of its 
deacetylase activity from its MARylation activity identified the latter to be important for its role in 
DSB repair. SIRT6 was shown to interact with and MARylate ARTD1, which in turn triggers the 
catalytic activity of ARTD1 and promotes DSB repair. Thus it appears that SIRT6 contributes to DSB 
repair indirectly through activating ARTD1 by MARylation [47]. In line with this, SIRT6 is also able 
to rescue the age-related decline in HR efficiency dependent on its ability to catalyze MARylation of 
ARTD1 [48]. 
Among the recently identified macrodomains capable of hydrolyzing MAR modifications, 
MACROD2 and C6ORF130/TARG1 have been shown to localize to sites of DNA damage when 
overexpressed [66,80]. TARG1 is important for DNA repair as cells depleted of TARG1 show 
increased sensitivity to DNA damaging agents. This suggests that these two enzymes are involved in 
regulating ADP-ribosylation in response to DNA damage. A possible scenario might be that to remove 
PARylation when ARTD1 was activated, first poly-ADP-ribosylglycohydrolase (PARG) and/or  
ADP-ribosylhydrolase 3 (ARH3) remove the polymers until the most proximal ADP-ribose unit. 
Because both enzymes cannot remove the ADP-ribose bound to the protein, the final step in 
completely removing PARylation requires MACROD2 and/or TARG1 or potentially other as yet 
unidentified enzymes. Furthermore MACROD2 and TARG1 are directly implicated in antagonizing 
the activities of ARTD8 and ARTD10, which are involved in DNA repair as discussed above. However, 
it should be noted that TARG1 may have a weak ability to revert PARylation directly by removing PAR 
chains [66]. These enzymes therefore seem to play a role for the (complete) turnover of  
ADP-ribosylation at DNA damage sites. They may also prevent over-activation of ARTD1 by 
counteracting initial ARTD1 auto-MARylation.  
Genomic instability and the acquisition of mutations are characteristic steps in tumorigenesis and 
can be caused by defects in proteins or pathways important for the detection or repair of damaged 
DNA. In light of the above-described recent findings concerning the functions of MARylation in DNA 
repair, writers and/or erasers of MARylation might as well contribute to cancer development when 
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deregulated or serve as therapeutic targets in the treatment of cancer, as it is already the case for their 
polymer-forming relatives [105]. 
3. MARylation in Disease 
3.1. Cancer and Metabolism 
NAD+ is an essential component of different cellular processes, including glycolysis and the 
transfer of electrons from NADH to the mitochondrial respiratory chain. In tumor cells, increased 
glycolysis is observed owing the highly increased demand of biomass [106,107]. To provide sufficient 
levels of NAD+, it is regenerated from NADH by a process catalyzed by lactate dehydrogenase, 
reducing pyruvate to lactate [108]. Thus NAD+ is closely associated with metabolic pathways not only 
in normal cells but particularly also in tumor cells. ARTDs and Sirtuins consume NAD+ in the process 
of ADP-ribosylating substrates, requiring a salvage pathway to recycle nicotinamide as well as a de 
novo synthesis pathway [109]. With these findings in mind it is not unexpected that enzymes that 
consume NAD+ are potentially involved in controlling metabolism and tumorigenic cell proliferation.  
Several reports indicate that MARylation is important for the regulation of cell proliferation [105,110]. 
Among those members of the ARTD family that exert MARylation activity, especially ARTD8 and 
ARTD10 have been demonstrated to modulate cell survival or apoptosis [25,26,34,84,105,110]. 
Moreover ARTD9, a catalytically inactive member of ARTDs, has been shown to regulate signaling as 
detailed below, suggesting that these ARTD members could contribute to cancer formation  
when deregulated.  
ARTD9 (PARP9/BAL1) was described as a risk factor for diffuse large B cell lymphoma (DLBCL) 
and therefore initially referred to as BAL1 (B-aggressive lymphoma 1) [27]. Although ARTD9 has 
been demonstrated to be catalytically inactive based on in vitro automodification studies [82], which is 
supported by structural considerations [6], it acts as an oncogenic factor in DLBCL [28] and possibly 
in metastatic prostate cancer cell lines [29]. In DLBCL, ARTD9 modulates interferon (IFN) γ-STAT1 
signaling in a way that induces a transcriptional switch resulting in the repression of tumor suppressor 
genes such as IRF1 and activation of proto-oncogenes. ARTD9 has two N-terminal  
ADP-ribose-binding macrodomains [27]. These macrodomains are responsible for interaction of 
ARTD9 with STAT1 and for its repressive effect on an IRF1 promoter-based luciferase reporter assay, 
suggesting that ADP-ribosylation of STAT1 mediates the interaction with ARTD9 [28]. In metastatic 
prostate cancer cell lines, survival and chemoresistance in response to IFNγ are mediated by ARTD9 
with its interaction partner DTX3L/BBAP in a STAT1-dependent way [29]. In addition, ARTD8 acts 
as a survival factor in these cell lines. ARTD8 was initially described as a BAL family member 
because of the structural similarities, i.e. the presence of both an ADP-ribosyltransferase domain and 
macrodomains, to ARTD9/BAL1 [82]. ARTD8 interacts with both DTX3L and ARTD9 but does not 
regulate the before mentioned IFNγ-STAT1-IRF1 axis. Thus whether ARTD8 is the enzyme that 
MARylates STAT1, which subsequently is read by ARTD9, remains to be determined. 
Furthermore, ARTD8 acts as a pro-survival factor in B cells. As a co-regulator of  
IL-4/STAT6-signaling, ARTD8 mediates IL-4-induced inhibition of apoptosis in B cells by regulating 
the expression of survival factors, repressing caspase-dependent apoptotic processes and regulating 
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glycolytic rates [25,26]. PJ-34 treatment protects B cells from apoptosis [25]. Although PJ-34 is an 
unspecific ARTD inhibitor, this suggest that ADP-ribosylation activity, possibly that of ARTD8, is 
involved in this process. Additionally, ARTD8 deficiency attenuates MYC-induced B cell lymphoma 
development in mice [26]. ARTD8 may also impact JNK signaling in multiple myeloma. It has been 
observed that constitutively active JNK2 suppresses JNK1-mediated apoptosis in these tumors [21]. 
This effect is mediated by ARTD8, whose expression depends on JNK2, and interacts with JNK1 
resulting in inhibition of its kinase activity. The interaction with JNK1 is restricted to ARTD8’s  
C-terminal region comprising the WWE and the catalytic domain [21]. Whether MARylation of, for 
example, JNK1 by ARTD8’s catalytic domain is important for JNK1 inhibition has not been 
investigated in detail. But as JNK1 activation and accordingly apoptosis of multiple myeloma cells 
occurs after treatment with PJ-34, catalytic activity of ARTD8 might be important in this process [21]. 
Altogether, this indicates that ARTD8 might be relevant as a therapeutic target in B cell malignancies 
and prostate cancer.  
In contrast to ARTD8, a first characterization of ARTD10 pointed to a growth-inhibitory role. 
ARTD10 was identified as an interaction partner of the oncoprotein c-MYC. In primary rat embryonic 
fibroblasts, ARTD10 inhibits MYC/Ha-RAS- and E1A/Ha-RAS-induced transformation independent 
of catalytic activity [84]. Unlike in these primary cells, in HeLa cells ARTD10 but not the catalytically 
inactive ARTD10-G888W mutant inhibits cell proliferation [6,34]. HeLa cells stably expressing 
ARTD10 are driven into apoptosis, probably mediated by MARylation of (so far not identified) 
ARTD10 substrate(s). During apoptosis induction, ARTD10 is exposed to caspase-6-mediated 
cleavage at D406 inactivating its pro-apoptotic properties [34]. As a non-cleavable mutant of ARTD10 
induces efficiently apoptosis and the cleavage products alone do not, it was suggested that the  
N-terminally located RRMs and the C-terminally located catalytic domain cooperate during apoptosis 
induction. How ARTD10 induces apoptosis mechanistically still remains to be clarified. Interestingly, 
knockdown of ARTD10 in HeLa cells results in growth inhibition as well [111], suggesting that a tight 
regulation of ARTD10 levels in cells is indispensable for normal cell growth. Interaction with c-MYC 
and its above-mentioned repressive role in NF-κB signaling might by relevant to control cell 
proliferation and apoptosis. The inflammatory NF-κB pathway is activated in many types of 
hematological malignancies and solid cancers. As a consequence, pro-proliferative and anti-apoptotic 
NF-κB target genes are induced, promoting tumor development [89,112]. To what extend ARTD10 
contributes to the pro-tumorigenic activities of NF-κB is a matter of current research.  
Besides ARTD8 and ARTD10, ARTD17 seems to be a regulator of cell proliferation. 
Overexpression of ARTD17 in HeLa cells inhibits cell growth dependent on the integrity of the 
catalytic domain and patients with ARTD17-positive colorectal cancer show higher survival rates 
compared to ARTD17-negative colorectal cancer patients [43]. 
ARTD4 has been identified as a component of vault particles [12]. Vaults are barrel-shaped 
ribonucleoprotein particles consisting of untranslated vault RNA molecules and the three proteins 
MVP (major vault protein), ARTD4 (vPARP, PARP4) and TEP1 (telomerase associated protein 1). 
The functions of vault particles are still not fully clear but roles in cellular transport, signaling, 
immunity and multidrug resistance have been discussed [13,14]. The exact role of ARTD4 in vault 
particles is unknown, but due to its up-regulation in some drug resistant cancer cell lines [15,16] one 
might speculate about an involvement of ARTD4 in the development of drug resistance in cancer. In 
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addition to vault particles, ARTD4 localizes to the nucleus and the mitotic spindle [12], so  
vault-independent functions are likely. Furthermore, ARTD4-deficient mice are prone to  
carcinogen-induced colon tumor formation [113].  
In addition to these members of the ARTD family, recent studies revealed that SIRT4 possesses 
tumor suppressor function [44–46], whereas SIRT6 has been reported to have both tumor suppressive 
and promoting functions [102]. SIRT4 is located to mitochondria and displays ADP-ribosyltransferase 
activity rather than deacetylase activity [44]. SIRT4 has been demonstrated to interact with and 
MARylate glutamate dehydrogenase (GDH), a metabolic enzyme catalyzing the conversion of 
glutamate to α-ketoglutarate, an intermediate of the TCA cycle (Figure 1) [44]. Thus, by negatively 
modulating the activity of GDH SIRT4 exerts a role in glutamine metabolism. Recently glutamine 
metabolism has been linked to genotoxic stress. DNA damage promotes upregulation of SIRT4 
expression, which subsequently results in downregulation of mitochondrial glutamine turnover [45]. 
Because glutamine metabolism is important for proliferation, particularly of tumor cells, and required 
for cell cycle transition from G1 to S phase, the cell cycle is arrested in consequence of reduced 
glutamine conversion [107]. This suggests that SIRT4 contributes to a metabolic checkpoint by 
regulation of GDH in response to genotoxic stress [45]. Besides this SIRT4 is also critical for genome 
integrity e.g. by facilitating clearance of γ-H2AX foci which arise at sites of DNA damage [45]. In line 
with this, SIRT4 is able to suppress tumor formation, whereas the loss of SIRT4 enables tumor 
formation at least in part by elevated glutamine metabolism, loss of the metabolic checkpoint and as a 
consequence genomic instability accompanied by enhanced proliferation. Indeed this has been 
observed in several tumor entities, including gastric adenocarcinomas, colorectal cancer and bladder 
cancer [45,114–116]. 
SIRT6 has been reported to have tumor suppressive functions. Its expression is reduced in several 
types of cancers [51–55]. Accordingly, overexpression of SIRT6 in different cancer cell lines reduces 
cell proliferation and induces apoptosis [51–53,56] Although some of these effects seem to be 
mediated by its deacetylase activity [55,57], SIRT6’s MARylation activity might as well be 
responsible for apoptosis induction [56]. Recently, MARylation activity of SIRT6 has been 
demonstrated to be important for transcriptional silencing of transposable elements. SIRT6 is 
associated with the 5’-UTR of L1 retrotransposons. SIRT6 regulates the recruitment of KAP1 and 
HP1α, factors associated with heterochromatin [50]. MARylation of KAP1 by SIRT6 promotes 
interaction between KAP1 and HP1α, thereby promoting the recruitment of HP1α to the L1 5’-UTR. 
This results in packaging of these retrotransposons into repressive heterochromatin [50]. During aging 
and in response to genotoxic stress, SIRT6 association with L1 is reduced or even lost. This activates 
the L1 retrotransposons, which can ultimately contribute to genomic instability and age-related 
diseases such as cancer [50]. It should be noted, however, that some reports state a more oncogenic 
function for SIRT6 [58,59]. Thus SIRT6 might have distinct functions depending on the type of cancer. 
Roles in the regulation of cell proliferation, cancer development and drug resistance have also been 
ascribed to the three so far identified MAR hydrolases. Several studies point to an association of 
MACROD1 (LRP16) with cancer. MACROD1 expression is induced by estrogen/estrogen receptor 
alpha (ERα) signaling in ERα-positive breast cancer cell lines [60,117]. Overexpression of the estrogen 
receptor and activated ERα signaling is observed in certain breast cancer subtypes but also in other 
tumors. Sustained activation of ERα signaling stimulates proliferation of mammary cells, eventually 
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leading to tumor formation [118]. MACROD1 interacts with ERα and functions in a positive feedback-
loop as a co-activator of ERα-dependent transcription, enhancing the expression of several ERα target 
genes, including c-MYC and CCND1, thereby provoking increased cell proliferation [60,61,117,119]. 
In analogy to its role in ERα signaling, MACROD1 interacts with and stimulates the transcriptional 
activity of the androgen receptor (AR) and in AR responsive prostate cancer cells, MACROD1 is 
needed for cell proliferation stimulated by testosterone [62]. Because the above described findings all 
rely on MACROD1’s macrodomain, which was recently shown to possess hydrolase activity 
specifically towards MARylation, one might speculate about a general involvement of MARylation in 
steroid hormone receptor signaling. Overexpression of MACROD1 might be associated with increased 
invasion, metastasis and shorter survival time in gastric and colorectal cancer [63,64]. Interestingly, a 
recent publication demonstrates that tamoxifen-resistance in breast tumors can be mediated by the 
related MACROD2 [65]. The authors observed amplification and overexpression of MACROD2 in 
tamoxifen-resistant breast cancer cell lines and in human breast cancer samples. MACROD2 
knockdown sensitizes tamoxifen resistant cells to tamoxifen treatment and reduces tumor formation of 
tamoxifen resistant cells in a xenograft model, suggesting that MACROD2 could become an important 
molecular target in the treatment of tamoxifen resistant breast cancer. 
Together the studies summarized above indicate involvement of enzymes controlling MARylation 
in cancer (Table 1). However, it is not clear whether any of the writers and erasers of MARylation 
function as oncoproteins or as tumor suppressors. Therefore we evaluated the mutational alterations 
associated with the different genes associated with MARylation, i.e. the mono-ARTs and -hydrolases, 
using COSMIC (Catalogue Of Somatic Mutations In Cancer; the analysis was performed on 03 July 
2015) [120]. All the genes analyzed (ARTD3, 4, 7–17, SIRT4, SIRT6, MACROD1, MACROD2, 
C6ORF130) are mutated at low frequency throughout their entire coding regions of more than 21.000 
tumors in the database. No accumulation of mutations in one particular tumor type is observed. Also 
there is no trend for specific protein regions being mutated such as the catalytic domains. This suggests 
that none of the analyzed genes is a hotspot for mutations in cancer. Also no translocations have been 
reported associated with these genes. Few cases with deletions or insertions are found in the COSMIC 
database but again no recurrent patterns are seen that would suggest these mutations being of patho-
physiological importance. 
Altered gene expression, with either a two-fold up- or down-regulation, is in most instances also 
rare. This goes with typically few copy number variant (CNV) gains or losses. However, a few 
findings are worth reporting as these might give indications for a contribution of a specific gene in 
certain tumors. For example ARTD3 is overexpressed in more than 30% of tumors of the large intestine 
but is underexpressed in about 26% of ovarian cancer. ARTD9, which is a risk factor for DLBCL, is 
up-regulated in many tumors with frequencies of up to 10%. ARTD10 is overexpressed in between 20 
and 30% of liver, esophagus, and ovarian cancer, and between 10 and 20% in cancer of the adrenal 
gland, the cervix, the stomach, and in head and neck squamous cell carcinoma. ARTD14 is 
overexpressed in more than 20% of esophageal cancer and in these tumors more than 12% show a 
CNV gain, suggesting that ARTD14 might be of functional relevance in esophageal cancer. The other 
genes are typically only affected in 10% or less cases of a given specific tumor. Down-regulation of 
these genes is observed very rarely and thus a role in tumor suppression is rather unlikely. Together, 
these findings suggest that the writers and readers of MARylation are affected in tumors but the 
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available data does not support a strong oncogenic or tumor suppressor function associated with these 
genes and proteins at present.  
3.2. Innate Immunity and Inflammation 
3.2.1. Mono-ARTDs in the Defense against Viral Infections 
The innate immune system represents the first line of defense against invading pathogens and 
operates during the first days of infection. It recognizes the nature of the invading pathogen through 
interactions of PAMPs and their respective cellular pattern recognition receptors and is able to activate 
adaptive immune responses [121]. A crucial component of innate immunity is cytokine-mediated 
signaling with the aim to inform and alarm neighboring (and immune) cells of the infection and induce 
defense mechanisms in an auto- and paracrine fashion. IFNs are cytokines produced upon viral 
infections with the aim to induce anti-viral responses via the induction of IFN-stimulated genes. 
Several mono-ARTDs are induced upon stimulation with type I IFNs and exert anti-viral effects. 
ARTD12 expression is induced by Toll-like receptor stimulation through LPS or IFNβ [35]. During 
Venezuelan Equine Encephalitis Virus (VEEV) infection, ARTD12 expression is up-regulated in a type 
I IFN-dependent manner [41]. The long isoform of ARTD12 as well as ARTD10 and ARTD14 inhibit 
replication of several RNA viruses like alphaviruses [31,41]. In addition, cellular translation is blocked 
after overexpression of these mono-ARTDs, which might account at least in part for an inhibition of 
viral replication. This is probably mediated by a concerted action of putative RNA binding motifs and 
catalytic domains as these three enzymes share a combination of such functional domains. As both 
ARTD10 and ARTD12 have been shown to localize to cytoplasmic structures containing the 
autophagic membrane adaptor protein p62, it has been speculated that both proteins regulate 
autophagic processes and might therefore affect pathogen clearance via autophagy [32,35]. This may 
be further affected by ARTD10 controlling NF-κB, which has also been implicated in the regulation of 
autophagy [30,122]. Moreover ARTD12 is able to induce expression of an NF-κB-responsive 
luciferase reporter plasmid and of endogenous NF-κB target genes [35]. As activation of NF-κB 
signaling is a key process in inflammation, MARylation by ARTD10 and ARTD12 might therefore 
modulate immune responses by targeting this pathway.  
A recent report demonstrated that several mono-ARTDs have evolved under positive selection [123]. 
This includes ARTD4, the three macrodomain-containing ARTDs, ARTD7, -8 and -9, and the 
catalytically inactive ARTD13 and indicates a direct involvement of these proteins in the defense 
against pathogens during recurrent conflicts of hosts with viral but also bacterial or eukaryotic 
pathogens. As mentioned above, ARTD4 is part of vault particles, which are linked to immunity and 
viral infection. Although precise functions of ARTD4 in these processes have not been described, it is 
hypothesized that this ARTD member is also involved in the anti-viral response [123]. ARTD13 (ZAP; 
zinc finger anti-viral protein) occurs in two isoforms. The short isoform lacks a C-terminal ART 
domain, whereas this domain is present but catalytically inactive in the long isoform [6]. ARTD13 
inhibits the replication of certain retro-, alpha-, filo- and hepadnaviruses [124–128]. Through its four 
CCCH-type zinc finger domains it binds viral mRNAs [129–131] and recruits the cellular RNA 
degradation machinery [126,128,131,132], thereby preventing the translation of viral RNAs and viral 
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replication. Thus, the anti-viral activity of ARTD13 is mainly accomplished by its N-terminal domain. 
However, the ARTD-like domain present in the long isoform might play a role in restricting the 
replication of alphaviruses [133].  
Although a direct role of ADP-ribosylation by ARTD13 can be excluded because ADP-ribosylation 
activity is lacking, crosstalk between other members of the ARTD family and ARTD13 might 
contribute to its cellular functions. Lately, ARTD13 was demonstrated to localize to stress granules 
(SGs) along with ARTD5, -7, -8, -12 and PARG [17]. SGs are dynamic ribonucleoprotein aggregations of 
translationally stalled mRNAs, ribosomal subunits and different RNA binding proteins [134]. They form 
upon different forms of cellular stress including oxidative stress, heat shock or nutrient starvation and 
regulate the stability or translation of mRNAs [134]. Overexpression of the SG-associated ARTDs is 
sufficient to induced SG assembly and several SG components are modified with ADP-ribose, as for 
example Ago2. Its modification by ADP-ribosylation is enhanced in response to stress [17]. 
Furthermore, ARTD13 regulates miRNA silencing [17]. MiRNA-mediated repression of target 
mRNAs is decreased after ARTD13 overexpression, PARG knockdown and upon stress. All of these 
conditions result in increased modification of Ago2 with ADP-ribose but also of ARTD13 itself [17]. 
This is established by interactions between ARTD13 and ARTD5, -7 and -12, as well as between Ago2 and 
ARTD5 and -12, and involves in trans mono- and poly-ADP-ribosylation by ARTD5, -7 and -12 [17,135]. 
PARG reverses these effects [17]. A tight regulation of MARylation and PARylation involving  
mono- and poly-ARTDs as well as PARG therefore seems to be important for the assembly of SGs and 
the function of miRNP complexes. As sites of silenced mRNA, SGs have been discussed regarding 
their role in viral infections [136,137]. In addition to the different forms of cellular stress that trigger 
SG assembly, SGs can be induced during infection of cells with certain viruses. Contrarily, some 
viruses actively inhibit SG formation during infection, suggesting that SGs can play an active role in 
anti-viral defense [136,137]. Although many open questions concerning the interplay of SGs and 
invading viruses need to be clarified in the future, one might speculate about a function of  
SG-associated ARTDs in viral defense by promoting SG formation [136,137]. 
Altogether this provides initial evidence that intracellular mono-ARTDs and MARylation play an 
important role in the host’s immune defense against infections. Accordingly, viruses might have 
developed mechanisms to evade the host’s immune defense involving ADP-ribosylation. RNA viruses 
of the Toga- and Coronaviridae families (for example alphaviruses including VEEV, Chikungunya 
virus (CHIKV), Sindbis virus (SINV); rubella virus; hepatitis E virus (HEV) and SARS-Coronavirus 
(SARS-CoV)) encode one or more macrodomains as part of non-structural proteins that are capable of 
binding to ADP-ribose and PAR [138,139]. In some cases, these domains are able to hydrolyze  
ADP-ribose-1′′-phosphate [138,140]. This raises the possibility that viral macrodomains could act as 
hydrolases for ADP-ribose modifications. A role of the viral macrodomains in counteracting the 
defense of host cells is strengthened by the fact that mutations in viral macrodomains result in a 
reduced virulence in mice [141,142] and mutation of the SARS-CoV macrodomain confers increased 
sensitivity to IFN treatment [143]. To what extent these macrodomains interfere with  
ADP-ribosylation in the host cell needs to be investigated in future studies. 
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3.2.2. Bacterial mono-ADP-ribosyltransferases  
As indicated above, SIRT4 and SIRT6 are two mammalian Sirtuins, which have been demonstrated 
to possess MARylation activity. It is interesting to note that also bacterial Sirtuins have been described 
as mono-ADP-ribosylating enzymes [70,144]. Recently substrate modification by the Sirtuins of 
Staphylococcus aureus and Streptococcus pyogenes, which are of a distinct Sirtuin subclass referred to 
as SirTMs, was demonstrated to be dependent on another PTM. Prior lipoylation of the substrate is 
necessary for efficient MARylation by these enzymes [144]. These Sirtuin genes are genetically linked 
to genes expressing macrodomain proteins, which are capable to revert SirTM-specific MARylation. 
The precise function of these mono-ADP-ribosyltransferase–hydrolase pairs remains to be determined. 
However, with the increasing accumulation of information that links MARylation to immune response 
and anti-viral activities, it is of interest to speculate that also bacterial pathogens use this PTM to 
counteract host defense.  
In addition to the rather recently discovered and still poorly explored bacterial Sirtuins, bacterial 
ARTs have long been known to affect cellular behavior by ADP-ribosylating specific host cell target 
proteins. Bacterial pathogens use toxins, including ARTs, to alter and kill host cells. A main purpose 
of these toxins is to disrupt immune cell functions and by this promote pathogen dispersal and 
proliferation, which is summarized in excellent reviews [145,146]. 
3.3.3. ARTD8 Modulates TH-Cell Differentiation 
The function of ARTD8 in STAT6-dependent transcriptional processes might be of physiological 
relevance for T and B cell responses in vivo. Deregulation of the TH2 response caused by disturbed  
IL-4/STAT6-signaling can contribute to the pathogenesis of inflammatory lung diseases such as 
asthma [83]. Reduced levels of TH2-specific cytokines IL-4, IL-5 and IL-13 were observed in in vitro 
differentiated TH2 cells isolated from ARTD8-deficient mice and after ARTD8 knockdown [22]. A 
model was proposed, in which ARTD8 regulates binding of STAT6 to the GATA3 promoter, thereby 
modulating T helper cell differentiation. Furthermore, the induction of allergic airway disease in this 
ARTD8 knockout mouse model resulted in immune cell infiltration into the lung associated with 
reduced levels of TH2 cytokines and chemokines as well as reduced IgE levels, arguing for a  
pro-allergic role of ARTD8. Moreover general inhibition of ARTD enzymatic activity by PJ-34 
reduced signs of the inflammatory TH2 response, although it has not been clarified if this effect is 
ascribed to ARTD8 inhibition only or if inhibition of other ARTD family members contributes to this 
phenotype. A possible role for ARTD8 in TH2 and IL-4-induced differentiation as well as in the IgE 
switch in B cells was also observed [23]. In addition, this group found that TH17 differentiation and 
accordingly production of IL-17 and -22 is impaired in ARTD8-deficient T cells as well depending on 
its catalytic activity, in turn affecting the induction of IgA responses in B cells [23,25]. If MARylation 
of HDAC2/3 and p100, transcriptional co-regulators of STAT6 (as described above), or MARylation 
of additional substrates plays a role in these processes, has not been investigated in these studies. 
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4. Conclusions 
The last several years have provided a number of lines of evidence to support the hypothesis that 
MARylation is involved in regulating several different physiological processes that include signaling 
pathways, gene transcription, DNA repair, and stress control. This is most likely the tip of the iceberg 
and we expect to see more evidence for regulatory functions of MARylation and the enzymes that 
control this PTM, i.e. the mono-ADP-ribosyltransferases and -hydrolases. In addition to studying the 
enzymes, we will need to understand how MARylation affects the function of target proteins and how 
the information is transmitted to other cellular components. One aspect of this is to define the readers 
of MARylation. Some macrodomains can bind to MARylated proteins but it seems likely that 
additional domains exist that connect this PTM to other cellular processes. Together interesting times 
are ahead of us that will shed more light on the regulatory roles MARylation plays in controlling cell 
physiology and organismal functions potentially associated with disease. 
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